247 related articles for article (PubMed ID: 33023532)
1. TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
Escalona RM; Bilandzic M; Western P; Kadife E; Kannourakis G; Findlay JK; Ahmed N
BMC Cancer; 2020 Oct; 20(1):960. PubMed ID: 33023532
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
4. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
5. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis.
Kim TJ; Rho SB; Choi YL; Choi CH; Lee JW; Bae DS; Ahn G; Lee JH; Kim BG
Hum Pathol; 2006 Jul; 37(7):906-13. PubMed ID: 16784992
[TBL] [Abstract][Full Text] [Related]
6. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
[TBL] [Abstract][Full Text] [Related]
7. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
9. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.
Kobayashi Y; Seino K; Hosonuma S; Ohara T; Itamochi H; Isonishi S; Kita T; Wada H; Kojo S; Kiguchi K
Gynecol Oncol; 2011 May; 121(2):390-4. PubMed ID: 21272926
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
11. Fibulin-5 is a tumour suppressor inhibiting cell migration and invasion in ovarian cancer.
Heo JH; Song JY; Jeong JY; Kim G; Kim TH; Kang H; Kwon AY; An HJ
J Clin Pathol; 2016 Feb; 69(2):109-16. PubMed ID: 26251522
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
14. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
15. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
16. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
17. Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.
Tang W; Ren A; Xiao H; Sun H; Li B
Biomed Pharmacother; 2017 Jan; 85():248-255. PubMed ID: 27908706
[TBL] [Abstract][Full Text] [Related]
18. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
19. Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
Soyama H; Miyamoto M; Takano M; Aoyama T; Matsuura H; Sakamoto T; Takasaki K; Kuwahara M; Kato K; Yoshikawa T; Iwahashi H; Tsuda H; Furuya K
Med Oncol; 2017 Nov; 34(12):201. PubMed ID: 29168038
[TBL] [Abstract][Full Text] [Related]
20. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
